A Pilot Study of the Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant
Latest Information Update: 17 Apr 2025
At a glance
- Drugs Interleukin-7 (Primary) ; Melphalan (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
Most Recent Events
- 09 Apr 2025 Planned End Date changed from 31 Mar 2029 to 30 Apr 2029.
- 09 Apr 2025 Planned primary completion date changed from 31 Mar 2029 to 30 Apr 2029.
- 09 Apr 2025 Status changed from not yet recruiting to recruiting.